Breast cancer

• Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or … Recruiting
  2023-507149-27-00 5 2019-11-04 "Chemotherapy-induced Thrombocytopenia in Adult subjects with"
• BRCA-P: A Cancer Prevention study to determine if Denosumab can prevent Breast Cancer Development in Women carrying a BRCA1 Germline Mutatio … Recruiting
  2024-513734-38-00 5 2019-07-03 "Prevention of breast cancer in women with a BRCA1 germline m"
• LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting
  2022-502706-33-00 6 2018-01-10 "Patients with invasive breast cancer in early stages"
• A Study to Test Inavolisib Treatments in Patients with Early-Stage, PIK3CA-Mutated Breast Cancer Recruitment ended
  2024-518811-20-00 4 2025-09-30 "Early-Stage, PIK3CA-Mutated Breast Cancer (BC)"
• Study of Zelenectide Pevedotin in Participants with Advanced Breast Cancer Recruitment ended
  2024-517868-33-00 4 2025-06-12 "NECTIN4 Amplified Advanced Breast Cancer"
• NEOadjuvant Abemaciclib and GIredestrant triaL in patients with ER-positive, HER2-negative Early breast cancer Recruitment ended
  2023-510153-42-00 4 2024-11-25 "ER-positive, HER2-negative Early breast cancer"
• The p53 breast cancer trial Recruitment ended
  2024-515135-29-00 4 2024-10-12 "breast cancer"
• NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+ … Recruitment ended
  2024-514458-61-01 4 2024-02-05 "HER2+ early breast cancer"
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients with Hormone Recepto … Recruitment ended
  2022-502322-41-00 5 2023-09-12 "Metastatic breast cancer"
• A Phase 1b/2 Study of PF-07220060 in Combination with PF-07104091 Plus Endocrine Therapy in Participants with BC and other Advanced Solid Tu … Recruitment ended
  2023-509504-15-00 4 2023-03-20 "HR-positive HER2-negative metastatic/advanced BC"
• [68Ga]Ga-ABY-025 PET in solid tumors Recruitment ended
  2022-500448-39-00 4 2022-11-20 "Gastro-esophageal cancer with HER2-expression (cohort 1). Br"
• A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsore … Recruitment ended
  2024-514891-41-00 6 2022-07-19 "HR+, HER2- advanced or metastatic breast cancer"
• This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in c … Recruitment ended
  2023-504491-15-00 1 2020-10-30 "Human epidermal growth factor receptor (HER2)-Expressing Can"
• Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Recruitment ended
  2023-510390-33-00 5 2020-10-23 "HER2-negative breast cancer patients with high relapse risk "
• A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi … Recruitment ended
  2023-509242-35-00 5 2020-07-23 "HR+/HER2- early breast cancer"
• Study comparing two standard treatments as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, … Recruitment ended
  2024-513005-31-00 5 2020-06-11 "Patients with untreated metastatic Estrogen Receptor positiv"
• Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk … Recruitment ended
  2024-515769-32-00 5 2019-07-02 "HR+/HER2- early breast cancer"
• Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib Recruitment ended
  2023-507329-40-00 6 2017-09-28 "1. Follicular Lymphoma 2. Chronic Lymphocytic Leukemia 3. Wa"
• Impact of 18F-FES TEP on therapeutical management in patients with metastatic breast cancer, ER positive and HER2 negative, in relapse after … Ended
  2024-517400-11-00 6 2024-10-24 "Patients with metastatic breast cancer initially presenting "
• To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination W … Ended
  2023-508124-36-00 1 2024-05-10 "Advanced or metastatic breast cancer and other advanced or m"
• Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors Ended
  2022-502867-39-00 1 2023-09-29 "Advanced solid tumors including non-small cell lung cancer ("
• Efficacy and Safety of Neoadjuvant Olaparib Monotherapy and Olaparib Plus Durvalumab Combination in HER2-Negative BRCAm Breast Cancer Ended
  2023-503529-20-00 4 2022-10-17 "BRCA Mutations and Early Stage HER2-Negative Breast Cancer"
• A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF CYC140, AN ORAL PLK1 INHIBITOR, IN SU … Ended
  2024-516290-67-00 9 2022-08-03 "ADVANCED SOLID TUMORS AND LYMPHOMA"
• A Study Evaluating Bemarituzumab in Solid Tumors with FGFR2b Overexpression Ended
  2023-505455-44-00 9 2022-06-29 "Solid tumours"

Showing 49–72 of 77 trials